Last reviewed · How we verify
normal injection of Enoxaparine
Enoxaparin is a low-molecular-weight heparin that inhibits blood clotting by enhancing the activity of antithrombin III against factors Xa and IIa.
Enoxaparin is a low-molecular-weight heparin that inhibits blood clotting by enhancing the activity of antithrombin III against factors Xa and IIa. Used for Prophylaxis of venous thromboembolism in surgical patients, Treatment of acute deep vein thrombosis, Treatment of acute pulmonary embolism.
At a glance
| Generic name | normal injection of Enoxaparine |
|---|---|
| Sponsor | French Cardiology Society |
| Drug class | Low-molecular-weight heparin (LMWH) |
| Target | Factor Xa and Factor IIa (via antithrombin III enhancement) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Enoxaparin binds to and potentiates antithrombin III, a natural anticoagulant, leading to inactivation of coagulation factors Xa and IIa. This prevents thrombin generation and fibrin formation, thereby reducing clot formation. It is administered by subcutaneous injection and has predictable pharmacokinetics compared to unfractionated heparin.
Approved indications
- Prophylaxis of venous thromboembolism in surgical patients
- Treatment of acute deep vein thrombosis
- Treatment of acute pulmonary embolism
- Prophylaxis in medically ill patients at risk of thromboembolism
- Acute coronary syndrome (unstable angina and non-ST-segment elevation myocardial infarction)
Common side effects
- Bleeding
- Thrombocytopenia
- Injection site hematoma
- Elevated transaminases
- Osteoporosis (with long-term use)
Key clinical trials
- Efficacy of Platelet-Rich Plasma Versus Mesotherapy in Androgenetic Alopecia: A Retrospective Study
- Effect of Vibration Anesthesia on Pain, Ecchymosis and Comfort Level in Subcutaneous Heparin Injection (NA)
- The Clinical Features and Pregnancy Outcomes of CTD Patients
- Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype (PHASE1, PHASE2)
- Rapid Atrial Fibrillation Treatment Strategy (PHASE4)
- Local Uterine Application of Low Molecular Weight Heparin (LMWH) in Intra-cytoplasmic Sperm Injection (ICSI) (PHASE1)
- Prophylaxis of Deep Vein Thrombosis Following Total Hip Arthroplasty (PHASE4)
- Adaptation Dose of Enoxaparin in Moderate Renal Failure Patients With Acute Coronary Syndrome (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- normal injection of Enoxaparine CI brief — competitive landscape report
- normal injection of Enoxaparine updates RSS · CI watch RSS
- French Cardiology Society portfolio CI